CR and CR/CRi rates were better among IC- and VEN + HMA–treated patients compared with HMA alone, but they were still low in comparison to the CR rate of 85% previously reported in TP53 wild-type AML [13, 37, 41]. The gene discussed is TP53; the disease is acute myeloid leukemia.